Kenvue
KVUE
17.53
-0.06
-0.34%
Kenvue
US · KVUE
#615 by market cap
Listed 2023
17.53
-0.06
-0.34%
Live - 5344 symbols - heartbeat 139s ago
· 2026-10-08 04:01
Pre-market
17.53
0.00%
After-hours
17.53
0.00%
Overnight
17.49
-0.23%
- Market cap
- 33.67B
- P/E (TTM)i
- 20.62
- P/Bi
- 3.19
- EPSi
- 0.76
- Div yieldi
- 4.73%
- 52W posi
- 67%
Reader sentiment
Are you bullish or bearish on KVUE?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.11, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 7 years
Latest year -2.14% YoY
Margins
- Gross margin
- 58.13%
- Operating margin
- 17.95%
- Net margin
- 9.72%
Key ratios & quality
- Enterprise valuei
- 41.04B
- Altman Z-Scorei
- 2.11
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2022 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 14.32B | 14.47B | 15.05B | 14.95B | 15.44B | 15.46B | 15.12B |
| Gross profit | 7.66B | 7.85B | 8.42B | 8.29B | 8.64B | 8.96B | 8.79B |
| Selling & admin expenses | 5.20B | 4.96B | 5.48B | 5.63B | 6.14B | 6.33B | 6.09B |
| Research & development | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 2.40B | 2.99B | 3.03B | 2.69B | 2.49B | 2.63B | 2.72B |
| Pretax profit | 2.12B | -1.02B | 2.93B | 2.64B | 2.19B | 1.42B | 2.00B |
| Tax | 685.00M | -137.00M | 847.00M | 573.00M | 526.00M | 385.00M | 529.00M |
| Net profit | 1.44B | -879.00M | 2.08B | 2.06B | 1.66B | 1.03B | 1.47B |
| Basic EPS | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| Diluted EPS | 0.76 | -0.47 | 1.10 | 1.09 | 0.90 | 0.54 | 0.76 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 3.74B | 3.84B | 3.76B | 3.78B | 3.91B | 3.96B |
| Gross profit | 2.17B | 2.26B | 2.23B | 2.14B | 2.30B | 2.30B |
| Selling & admin expenses | 1.54B | 1.50B | 1.51B | 1.54B | 1.45B | 1.54B |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 618.00M | 752.00M | 713.00M | 632.00M | 838.00M | 758.00M |
| Pretax profit | 458.00M | 588.00M | 526.00M | 427.00M | 672.00M | 598.00M |
| Tax | 136.00M | 168.00M | 128.00M | 97.00M | 198.00M | 142.00M |
| Net profit | 322.00M | 420.00M | 398.00M | 330.00M | 474.00M | 456.00M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.17 | 0.22 | 0.21 | 0.17 | 0.25 | 0.24 |
Balance sheet
| Line item | 2019 | 2020 | 2022 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total current assets | -- | 4.60B | 4.93B | 5.88B | 6.14B | 5.53B | 5.70B |
| Cash & ST investments | -- | 618.00M | 740.00M | 1.23B | 1.38B | 1.07B | 1.06B |
| Inventory | -- | 1.69B | 1.70B | 2.23B | 1.85B | 1.59B | 1.67B |
| Total assets | -- | 29.18B | 27.93B | 27.32B | 27.85B | 25.60B | 27.08B |
| Total current liabilities | -- | 7.49B | 4.04B | 3.93B | 5.48B | 5.74B | 5.95B |
| Short-term debt | -- | -- | 47.00M | 35.00M | 643.00M | 1.59B | 1.50B |
| Long-term debt | -- | -- | -- | -- | 7.69B | 6.94B | 6.94B |
| Total liabilities | -- | 10,821,000,000.00 | 7,530,000,000.00 | 7,346,000,000.00 | 16,640,000,000.00 | 15,933,000,000.00 | 16,311,000,000.00 |
| Total equity | -- | 18.36B | 20.40B | 19.97B | 11.21B | 9.67B | 10.77B |
| Retained earnings | -- | -- | -- | 0 | 429.00M | -93.00M | -204.00M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 5.71B | 5.85B | 6.03B | 5.70B | 5.80B | 5.90B |
| Cash & ST investments | 1.06B | 1.07B | 1.14B | 1.06B | 1.08B | 1.11B |
| Inventory | 1.68B | 1.78B | 1.79B | 1.67B | 1.67B | 1.72B |
| Total assets | 26.26B | 27.13B | 27.25B | 27.08B | 26.85B | 26.74B |
| Total current liabilities | 6.67B | 5.99B | 6.16B | 5.95B | 5.90B | 5.87B |
| Short-term debt | 2.47B | 1.59B | 1.95B | 1.50B | 1.63B | 1.45B |
| Long-term debt | 6.20B | 7.06B | 7.06B | 6.94B | 7.07B | 7.07B |
| Total liabilities | 16,204,000,000.00 | 16,402,000,000.00 | 16,614,000,000.00 | 16,311,000,000.00 | 16,246,000,000.00 | 16,182,000,000.00 |
| Total equity | 10.05B | 10.73B | 10.63B | 10.77B | 10.61B | 10.55B |
| Retained earnings | -163.00M | -136.00M | -136.00M | -204.00M | -128.00M | -70.00M |
Cash flow
| Line item | 2019 | 2020 | 2022 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 3.00B | 3.40B | 334.00M | 2.53B | 3.17B | 1.77B | 2.20B |
| Depreciation & amortization | 709.00M | 746.00M | 731.00M | 644.00M | 627.00M | 622.00M | 557.00M |
| Free cash flow | 2.71B | 3.17B | 39.00M | 2.15B | 2.70B | 1.34B | 1.72B |
| Dividends paid | -- | -- | 0 | 0 | -14.55B | -1.55B | -1.58B |
| Stock buybacks / issuance | -- | -- | 0 | 0 | 4.23B | -235.00M | -197.00M |
| Ending cash balance | 752.00M | 618.00M | 740.00M | 1.23B | 1.38B | 1.07B | 1.06B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 428.00M | 621.00M | 294.00M | 854.00M | 489.00M | 688.00M |
| Depreciation & amortization | 136.00M | 142.00M | 141.00M | 138.00M | 143.00M | 145.00M |
| Free cash flow | 249.00M | 533.00M | 196.00M | 744.00M | 350.00M | 624.00M |
| Dividends paid | -392.00M | -393.00M | -398.00M | -398.00M | -398.00M | -398.00M |
| Stock buybacks / issuance | -63.00M | -64.00M | -70.00M | 0 | 0 | 0 |
| Ending cash balance | 1.06B | 1.07B | 1.14B | 1.06B | 1.08B | 1.11B |
Returns & efficiency
| Line item | 2019 | 2020 | 2022 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| ROE %i | -- | -4.79 | 10.48 | 9.27 | 14.99 | 9.87 | 14.39 |
| ROA %i | -- | -3.01 | 7.11 | 5.26 | 6.03 | 3.85 | 5.58 |
| ROIC %i | -- | -4.79 | 10.48 | 5.91 | 9.22 | 6.86 | 9.25 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | 7.34 | 11.18 |
| EBIT margin %i | 16.75 | 20.65 | 20.01 | 16.52 | 16.50 | 11.94 | 16.06 |
| FCF / sales %i | 18.91 | 21.90 | 0.26 | 14.38 | 17.48 | 8.64 | 11.39 |
| Current ratioi | -- | 0.61 | 1.22 | 1.50 | 1.12 | 0.96 | 0.96 |
| Quick ratioi | -- | 0.37 | 0.76 | 0.90 | 0.73 | 0.65 | 0.65 |
| Debt / assetsi | -- | -- | 0.46 | 0.42 | 30.26 | 34.06 | 32.04 |
| LT debt / equityi | -- | -- | 0.40 | 0.41 | 69.43 | 73.77 | 66.68 |
| Interest coveragei | -- | -- | -- | -- | 7.12 | 4.28 | 5.65 |
| Revenue CAGR (3Y) %i | -- | -- | -- | 1.44 | 2.20 | 0.88 | 0.39 |
| Net income CAGR (3Y) %i | -- | -- | -- | 12.88 | -- | -20.86 | -10.70 |
| FCF CAGR (3Y) %i | -- | -- | -- | -7.41 | -5.20 | 224.69 | -7.13 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 10.22 | 13.56 | 13.47 | 14.39 | 15.70 | 15.58 |
| ROA %i | 3.94 | 5.29 | 5.29 | 5.58 | 6.11 | 6.16 |
| ROIC %i | 6.97 | 8.84 | 8.74 | 9.25 | 9.92 | 10.03 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 12.25 | 15.84 | 15.64 | 16.06 | 17.28 | 17.19 |
| FCF / sales %i | 9.48 | 10.79 | 10.92 | 11.39 | 11.92 | 12.42 |
| Current ratioi | 0.86 | 0.98 | 0.98 | 0.96 | 0.98 | 1.01 |
| Quick ratioi | 0.58 | 0.66 | 0.66 | 0.65 | 0.68 | 0.69 |
| Debt / assetsi | 33.72 | 32.23 | 33.43 | 32.04 | 32.78 | 32.22 |
| LT debt / equityi | 63.51 | 66.66 | 67.31 | 66.68 | 67.60 | 67.90 |
| Interest coveragei | 4.37 | 5.58 | 5.47 | 5.65 | 6.16 | 6.23 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Diversified
- Self Care is the largest reported line at 40.18% of revenue, across 3 reported segments.
- No single line clears half of revenue; Essential Health is next at 31.68%, spreading the business across more than one real driver.
Revenue breakdown most recent period
Business
Self Care40.18%
Essential Health31.68%
Skin Health and Beauty28.14%
Quote time 2026-10-08 04:01:02 · For reference only, not investment advice and not tailored to your situation.